Learn more Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring ...

The U.S. Food and Drug Administration on Friday proposed to reduce animal studies conducted to assess safety in the development of certain cancer medications, marking the agency’s latest effort to ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...

An artificial intelligence model from the Mayo Clinic detected early signs of possible pancreatic cancer on scans up to two years before patients were diagnosed.

Pfizer Inc. PFE and China’s Innovent Biologics have announced a global licensing and collaboration agreement. The deal, valued at up to $10.5 billion, is set to develop 12 early-stage cancer drugs.

A cancer diagnosis changes how people measure time. This article explores how advances in oncology research, precision ...

Pfizer and China’s Innovent Biologics signed a global agreement worth up to $10.5 billion, including a $650 million upfront ...